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Abstract
Background Obesity, a known risk factor for chronic kidney disease (CKD), is generally assessed using body mass index (BMI).
However, BMI may not effectively reflect body composition, and the impact of muscle-to-fat (MF) mass balance on kidney
function has not been elucidated. This study evaluated the association between body muscle and fat mass balance, repre-
sented as the MF ratio, and incident CKD development.
Methods Data were retrieved from a prospective community-based cohort study (Korean Genome and Epidemiology Study).
Muscle and fat mass were measured using multifrequency bioelectrical impedance analysis. The study endpoint was incident
CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2 in at least two or more consecutive measurements during the
follow-up period).
Results Totally, 7682 participants were evaluated. Their mean age was 51.7 ± 8.7 years, and 48% of the subjects were men.
During a median follow-up of 140.0 (70.0–143.0) months, 633 (8.2%) subjects developed incident CKD. When the association
between body composition and incident CKD was investigated, multivariable Cox proportional hazard analysis revealed that
increase in MF ratio was related with a decreased risk of CKD development [per 1 increase in MF ratio: hazard ratio (HR),
0.86; 95% confidence interval (CI), 0.77–0.96; P = 0.008]. This association was also maintained when MF ratio was dichoto-
mized according to sex-specific median values (high vs. low: HR, 0.83; 95% CI, 0.70–0.98; P = 0.031). Analyses preformed in
a propensity score matched group also revealed a similar decreased risk of incident CKD in high MF ratio participants (high
vs. low: HR, 0.84; 95% CI, 0.71–0.98; P = 0.037). This relationship between MF ratio and incident CKD risk was consistently
significant across subgroups stratified by age, sex, hypertension, estimated glomerular filtration rate categories, and protein-
uria. Among different BMI groups (normal, overweight, and obese), the relationship between high MF ratio and lower incident
CKD risk was significant only in overweight and obese subjects.
Conclusions Lower fat mass relative to muscle mass may lower the risk of CKD development in individuals with normal renal
function. This relationship seems more prominent in overweight and obese subjects than in normal weight subjects.
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Introduction
Obesity is considered a major public health problem owing to
its rapidly increasing prevalence and close association with
poor outcomes.1 A commonly used measure for assessing ad-
iposity is body mass index (BMI).2 Studies have shown BMI to
be a significant risk factor for the development of various
acute and chronic conditions such as hypertension, type 2
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diabetes, cardiovascular diseases (CVDs), and certain types of
cancer.3 Several recent large epidemiologic investigations
have also reported that the risk of chronic kidney disease
(CKD) development clearly increases with the increase in
BMI.4 However, others have failed to observe such
associations.5,6
One major shortcoming of using BMI to determine obesity
is that BMI does not account for body composition.7,8 BMI,
calculated based only on height and weight, is an inaccurate
measure of body fat content and does not take into account
the fluid status, muscle mass, or bone density.9,10 Individuals
with the same BMI may largely vary in body composition. This
inaccuracy of BMI in representing adiposity may be one of
the reasons for the controversial results among studies eval-
uating the association between BMI and CKD development.
Recent studies have suggested that body fat mass and
muscle mass may differently affect health outcomes. An in-
crease in muscle mass has been linked to less insulin resis-
tance and protection against the development of type 2
diabetes.11–13 In addition, a lower amount of lean body mass
has been reported to be related to an increased risk of car-
diovascular events.14,15 On the other hand, increased fat
mass has been shown to increase the risk of metabolic de-
rangements and poor cardiovascular outcome.16,17 More-
over, the substantial loss of muscle mass relative to fat
mass, termed as ‘sarcopenia’, has been found to have a neg-
ative effect on various cardiometabolic parameters and on
mortality.18–20 This relationship has been observed not only
in the elderly population and in patients with cancer, in
whom muscle loss is prevalent, but also in the general popu-
lation.10,21 Nonetheless, the impact of muscle mass to fat
mass balance on kidney function has not been clearly
elucidated.
Therefore, the present study aimed to evaluate the associ-
ation between the balance of body muscle and fat mass com-
position, represented as the muscle-to-fat (MF) ratio, and
incident CKD development in a prospective community-based
cohort of subjects with normal renal function.
Materials and methods
Study subjects
This study used data from the Korean Genome and Epidemi-
ology Study (KoGES), a prospective community-based cohort
study. The detailed profile and methods of how the KoGES
cohort was assembled were previously described else-
where.22 Briefly, the study cohort consisted of 10 030 sub-
jects aged 40–69 years who were residents of Ansan or
Ansung, which are cities near the capital city of Seoul,
South Korea. The subjects underwent medical health evalua-
tions and various surveys at baseline. Serial health
examinations and surveys were performed biennially from
2001 to 2014. In this study, subjects with available body com-
position data were initially screened for inclusion. Subse-
quent exclusions were performed for those with an
estimated glomerular filtration rate (eGFR) of <60 mL/min/
1.73 m2 or underlying kidney disease at baseline, those with
missing data, and those with missing follow-up creatinine
data. A total of 7682 subjects were included in the final anal-
ysis (Supporting Information, Figure S1). All subjects voluntar-
ily participated in the study and provided informed consent.
The study protocol was approved by the Ethics Committee
of KoGES at the Korean National Institute of Health. This
study was performed in accordance with the Declaration of
Helsinki and approved by the institutional review board of
Yonsei University Health System Clinical Trial Center (4-
2016-0900).
Anthropometric and laboratory data
All subjects underwent a comprehensive medical health ex-
amination and completed questionnaires about health and
lifestyle factors at the time of study entry. Demographic
and socio-economic data, including age, sex, education and
income level, smoking status, alcohol intake, and medical his-
tories, were obtained. Anthropometric parameters such as
height and weight were measured by trained researchers ac-
cording to a specific protocol in which the subjects took off
their shoes, wore light clothing, and stood on a scale on an
even surface while measurements were taken. Education
level was classified into three groups: low, lower than middle
school; middle, middle school; and high, higher than middle
school. Income level was divided into tertile groups based
on the average per-person monthly income: low, <$850 per
month; middle, $850–1700 per month; and high, ≥$1700
per month. Physical activity status was categorized into active
(at least 30 min/day of moderate-intensity activity) or inac-
tive. Subjects who had a blood pressure of ≥140/90 mmHg
or were taking antihypertensive agents were considered to
have hypertension. Those who had a blood glucose level of
≥126 mg/dL in an 8 h fasting status, had a post-load glucose
level of ≥200 mg/dL after a 75 g oral glucose tolerance test,
had a haemoglobin A1c (HbA1c) value of ≥6.5%, or were tak-
ing oral medication and/or receiving insulin treatment for
hyperglycaemia were considered to have diabetes. Subjects
who had a medical history of dyslipidaemia or were taking
medications for lipid control were considered to have
dyslipidaemia. CVDs were defined as the composite of myo-
cardial infarction, congestive heart failure, and coronary ar-
tery disease.
Blood and urine samples were obtained after an 8 h fast
and transported to a central laboratory (Seoul Clinical Labora-
tories, Seoul, Republic of Korea) within 24 h of sampling. The
serum concentrations of blood urea nitrogen, creatinine,
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albumin, glucose, total cholesterol, triglyceride, high-density
lipoprotein cholesterol (HDL-C), and C-reactive protein (CRP)
were measured using ADVIA 1650 (Siemens, Tarrytown, NY,
USA). Serum creatinine level was measured using the Jaffé
method throughout the study period. The creatinine levels
were reduced by a calibration factor of 5% for standardiza-
tion to isotope dilution mass spectrometry reference method
values.23 Low-density lipoprotein cholesterol (LDL-C) level
was calculated using the following formula: [total cholesterol
(mg/dL)  HDL-C (mg/dL)  triglyceride (mg/dL) /5]. The
HbA1c level was determined using high-performance liquid
chromatography (Variant II; BioRad Laboratories, Hercules,
CA, USA). Haemoglobin levels were measured using an
autoanalyser (Sysmex, Kobe, Japan). Homeostatic model as-
sessment of insulin resistance (HOMA-IR) was calculated by
following formula: [fasting insulin (uU/mL) × fasting plasma
glucose (mg/dL) /405]. Urine samples were collected in the
morning after the first voiding and subjected to a dipstick test
using URISCAN Pro II (YD Diagnostics Corp., Seoul, Korea).
Proteinuria was quantified as absent, trace, 1+, 2+, or 3+
based on a colour scale. The presence of proteinuria was de-
fined as a dipstick urine test result of more than or equal to
the trace level.
Assessment of body composition
Body composition was assessed using multifrequency bio-
electrical impedance analysis (BIA; InBody 3.0, Biospace,
Seoul, Korea). Compared with conventional BIA-based analy-
sis methods that rely on formulae to calculate the estimated
mass of each body component, multifrequency BIA assumes
that the human body consists of five interconnecting cylin-
ders and performs impedance measurements directly on
these compartments. Using a tetrapolar 8-point tactile elec-
trode system, impedances were measured at four specific
frequencies (5, 50, 250, and 500 kHz) in five segments (right
arm, left arm, trunk, right leg, and left leg). Muscle mass
and fat mass were expressed as the muscle mass index
(MMI, muscle mass/height2) and the fat mass index (FMI,
fat mass/height2), respectively. The MF ratio was defined as
MMI/FMI. BMI was calculated as weight divided by height
squared (kg/m2). Subjects were allocated into two groups
based on the sex-specific median values of the MF ratio.
Sex-specific median value of the MF ratio was defined as
the median of the MF ratio in men and women, separately.
The World Health Organization obesity classification for Asian
populations was used to determine overweight and obesity.
Study outcome
The primary endpoint was incident CKD development. CKD
was defined as an eGFR of <60 mL/min/1.73 m2 in at least
two or more consecutive measurements during the follow-
up period. The eGFR was calculated using the CKD Epidemiol-
ogy Collaboration equation.24
Statistical analysis
All statistical analyses were performed using IBM SPSS soft-
ware for Windows version 23.0 (IBM Corporation, Armonk,
NY, USA), SAS software version 9.2 (SAS Institute Inc., Cary,
NC, USA), and R software 3.3.1 (http://www.R-project.org).
Continuous variables were expressed as means ± standard
deviations, and categorical variables were expressed as abso-
lute numbers with percentages. All data were tested for nor-
mality before statistical analysis. The Kolmogorov–Smirnov
test was performed to determine the normality of the distri-
bution of the parameters. Intergroup comparisons were per-
formed using analysis of variance or Student’s t-test for
normally distributed continuous variables, whereas categori-
cal variables were examined using the χ2 test or Fisher’s exact
test. Data that did not show normal distribution were pre-
sented as medians with interquartile ranges and compared
using the Mann–Whitney U test or Kruskal–Wallis test. Cumu-
lative renal survival rates were estimated using Kaplan–Meier
analyses and log-rank tests. Survival time was defined as the
time interval between baseline and the onset of outcome or
the last follow-up. Subjects who were lost during follow-up
were censored in the final analysis. Cox proportional hazard
models were constructed to determine the independent pre-
dictive value of the MF ratio for incident CKD development.
Variables that presented statistical significance in the
univariable analysis were included in the multivariable
models (Supporting Information, Table S1). Model 1 was
not adjusted for any covariates. Model 2 included baseline
age and sex. Model 3 included demographic factors and co-
morbidities. Model 4 was further adjusted for laboratory pa-
rameters. For the propensity score matching (PSM) analyses,
the propensity score was determined using binary logistic re-
gression with greedy nearest neighbour matching technique
without replacement. A caliper of 0.2 times the standard de-
viation was used. Subjects with high MF ratio were matched
to those with low MF ratio. In the matched cohort, the
groups were compared with paired t-test and McNemar test,
as appropriate. To test the relationship between incident CKD
risk and MF ratio as a continuous variable, restricted cubic
spline analyses were conducted. Extreme outliers, defined
as values less than first quartile (Q1)  1.5 × interquartile
range (Q3–Q1) or greater than third quartile (Q3) + 1.5 × in-
terquartile range, were excluded when depicting the cubic
spline analysis results. For sensitivity analysis, analyses were
conducted with creatinine levels adjusted through a conver-
sion equation different from the formula used in the main
analyses.25,26 P-values of <0.05 were considered statistically
significant.
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The baseline characteristics of the study subjects according to
the sex-specific median values of the MF ratio are described
in Table 1. The median MF ratio was 3.4 [2.8–4.2] and 2.0
[1.7–2.3] in male and female participants, respectively. The
mean age was 51.4 ± 8.7 years, and 3686 (48%) subjects were
men. The mean eGFR was 93.9 ± 14.2 mL/min/1.73 m2. The
MMI, FMI, BMI, and waist-to-hip ratio were significantly
lower in the high MF ratio group than in the low MF ratio
group. Subjects in the high MF ratio group were younger
and were more likely to be physically active than those in
the low MF ratio group. However, the proportions of men,
smokers, and alcohol drinkers were comparable between
the groups. Subjects in the high MF ratio group were more
likely to engage in physical activities than those in the low
MF ratio group. The systolic blood pressure (SBP) was lower,
and fewer subjects had co-morbidities such as hypertension,
diabetes, dyslipidaemia, and CVDs in the high MF ratio group
than in the low MF ratio group. With respect to laboratory
test results, eGFR was higher and the proportion of
proteinuria-positive subjects was lower in the high MF ratio








(n = 3843) P
Body composition
MF ratio 2.9 ± 1.2 2.2 ± 0.6 3.5 ± 1.3 <0.001
Muscle mass index (kg/m2) 16.8 ± 1.7 17.2 ± 1.7 16.4 ± 1.7 <0.001
Fat mass index (kg/m2) 6.8 ± 2.4 8.3 ± 2.1 5.2 ± 1.6 <0.001
BMI (kg/m2) 24.6 ± 3.1 26.5 ± 2.6 22.7 ± 2.2 <0.001
WHR 0.87 ± 0.08 0.90 ± 0.07 0.85 ± 0.07 <0.001
Demographic data
Age (years) 51.4 ± 8.7 52.3 ± 8.7 50.4 ± 8.6 <0.001
Male, n (%) 3686 (48.0) 1846 (48.1) 1840 (47.9) 0.437
Smoking status, n (%) 3129 (41.2) 1533 (40.4) 1596 (42.0) 0.083
Alcohol status, n (%) 4143 (54.4) 2050 (53.8) 2093 (54.9) 0.173
Physical activity status, n (%) 3796 (50.7) 1821 (48.6) 1975 (52.8) <0.001
Physical activity (Mets) 9095.1 ± 6037.2 8492.5 ± 5736.9 9697.1 ± 6266.1 <0.001
SBP (mmHg) 121.0 ± 18.4 124.3 ± 18.7 117.6 ± 17.5 <0.001
Education, n (%) <0.001
Low 2282 (29.9) 1223 (32.1) 1059 (27.7)
Intermediate 4214 (55.3) 1999 (52.5) 2215 (58.0)
High 1130 (14.8) 584 (15.3) 546 (14.3)
Income, n (%) 0.372
Low 2357 (31.2) 1196 (31.7) 1161 (30.6)
Intermediate 2185 (28.9) 1064 (28.2) 1121 (29.6)
High 3019 (39.9) 1512 (40.1) 1507 (39.8)
Co-morbidities, n (%)
Hypertension 1071 (13.9) 740 (19.3) 331 (8.6) <0.001
Diabetes 493 (6.4) 294 (7.7) 199 (5.2) <0.001
Dyslipidaemia 203 (2.6) 122 (3.2) 81 (2.1) 0.002
CVDs 105 (1.4) 70 (1.8) 35 (0.9) <0.001
Laboratory data
eGFR (mL/min/1.73 m2) 93.9 ± 14.2 92.9 ± 14.1 94.9 ± 14.3 <0.001
Proteinuria (%) 581 (7.6) 321 (8.4) 260 (6.8) 0.005
Haemoglobin (g/dL) 13.6 ± 1.6 13.8 ± 1.5 13.4 ± 1.6 <0.001
Albumin (g/dL) 4.52 ± 0.28 4.53 ± 0.28 4.51 ± 0.29 0.003
Total cholesterol (mg/dL) 199.1 ± 36.7 206.3 ± 36.9 191.8 ± 35.1 <0.001
LDL-C (mg/dL) 119.2 ± 34.5 124.1 ± 35.0 114.2 ± 33.2 <0.001
HDL-C (mg/dL) 49.5 ± 11.8 47.5 ± 10.7 51.6 ± 12.4 <0.001
Triglyceride (mg/dL) 151.8 ± 108.3 173.5 ± 119.0 130.1 ± 91.3 <0.001
Fasting glucose (mg/dL) 92.6 ± 23.2 95.2 ± 24.7 90.0 ± 21.2 <0.001
HbA1c (%) 5.8 ± 0.9 5.9 ± 0.9 5.7 ± 0.8 <0.001
HOMA-IR 1.7 ± 1.2 2.0 ± 1.4 1.5 ± 1.1 <0.001
CRP [IQR] (mg/dL) 0.14 [0.06–0.25] 0.17 [0.09–0.28] 0.12 [0.05–0.20] <0.001
Data are presented as mean (standard deviation), median [interquartile range], or number (%). Sex-specific median of the MF ratio was
3.4 [2.8–4.2] in men and 2.0 [1.7–2.3] in women. BMI, body mass index; CRP, C-reactive protein; CVDs, cardiovascular diseases; eGFR, es-
timated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HbA1c, haemoglobin A1c; HOMA-IR, homeostatic model
assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; MF ratio, muscle-to-fat ratio; SBP, systolic blood pressure;
WHR, waist-to-hip ratio.
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group than in the low MF ratio group. The levels of
haemoglobin, albumin, total cholesterol, LDL-C, triglyceride,
fasting plasma glucose, HbA1c, HOMA-IR, and CRP were sig-
nificantly lower in the high MF ratio group than in the low
MF ratio group.
When the baseline characteristics were compared be-
tween male and female participants, male subjects were
younger. In addition, male participants had a higher MF-ratio,
MMI, and WHR. The FMI and BMI were lower in males com-
pared to female participants. Male participants were more
likely to smoke and drink alcohol and have a higher education
and income than female participants. In addition, hyperten-
sion was more common while diabetes and dyslipidaemia
were less common among men than women. Regarding labo-
ratory test results, eGFR, LDL-C, and HDL-C levels were lower
while haemoglobin, serum albumin, triglyceride, fasting glu-
cose, HOMA-IR, and CRP levels were higher among men than
among women (Supporting Information, Table S2).
Relationship between muscle-to-fat ratio and
metabolic factors
The associations between body composition indices and met-
abolic variables are shown in Supporting Information, Table
S3. BMI revealed a positive relationship with SBP and total
cholesterol, LDL-C, triglyceride, HOMA-IR, and CRP levels,
whereas age and eGFR were negatively associated with each
other. The MF ratio showed a positive association with serum
albumin level, whereas a negative association was found
among age, SBP, eGFR, and total cholesterol, LDL-C, triglycer-
ide, HOMA-IR, and CRP levels.
When the relationship between body composition compo-
nents and BMI was evaluated, a strong negative correlation
was found between the MF ratio and BMI (β = 0.560,
Supporting Information, Figure S2A). However, both the
MMI and FMI showed a positive association with BMI (β =
0.618 and β = 0.809, respectively; Supporting Information,
Figure S2B and S2C).
Association between muscle-to-fat ratio and
chronic kidney disease development
During a median follow-up of 140.0 (70.0–143.0) months, 633
(8.2%) subjects developed incident CKD. The follow-up dura-
tion was similar between the high and low MF ratio groups
[140.0 (69.9–143.0) vs. 141.0 (71.0–143.1) months, P =
0.140]. Cox proportional hazard analyses were performed to
assess the association between the MF ratio and CKD devel-
opment. When BMI was dichotomized according to the sex-
specific median values, CKD development risk was signifi-
cantly increased in the high BMI group compared with the
low BMI group in the unadjusted model [hazard ratio (HR),
1.37; 95% confidence interval (CI), 1.17–1.60]. However,
when adjustments were made for confounding factors, the
elevated CKD risk in the high BMI group was no longer signif-
icant (HR, 1.10; 95% CI, 0.93–1.31). On the other hand, CKD
development risk was significantly decreased in the high MF
ratio group than in the low MF ratio group, even after
adjusting for confounding variables (HR, 0.83; 95% CI, 0.70–
0.98). A similar association was found when MF ratio was
considered as a continuous variable (Table 2). When re-
stricted cubic spline analyses were further conducted, CKD
development risk was noted to gradually decrease signifi-
cantly with the increase of MF ratio (Supporting Information,
Figure S3).
In order to further minimize the effect of confounding fac-
tors, the risk for incident CKD was further determined in 3280
participants matched by propensity score. As shown in
Supporting Information, Table S4, the high and low MF ratio
groups were well matched for baseline characteristics after
PSM. Cox proportional hazard analyses preformed in the
PSM group revealed that participants with a high MF ratio
were associated with a significantly decreased risk of incident
CKD compared with those with a low MF ratio (HR, 0.84; 95%
CI, 0.71–0.98), a finding consistent with the result of the non-
matched cohort (Supporting Information, Table S5).
For sensitivity analysis, evaluations were also performed
with creatinine levels that were adjusted using a conversion
equation different from the formula used in the main analy-
Table 2 Risk of chronic kidney disease development according to body composition indices
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
BMI
Per 1 kg/m2 increase 1.08 (1.05–1.11) <0.001 1.08 (1.06–1.11) <0.001 1.05 (1.02–1.08) <0.001 1.04 (0.99–1.08) 0.059
High vs. low 1.37 (1.17–1.60) <0.001 1.48 (1.26–1.73) <0.001 1.22 (1.04–1.45) 0.017 1.10 (0.93–1.31) 0.245
MF ratio
Per 1 increase 0.75 (0.69–0.82) <0.001 0.74 (0.67–0.82) <0.001 0.82 (0.74–0.91) <0.001 0.86 (0.77–0.96) 0.008
High vs. low 0.68 (0.58–0.80) <0.001 0.68 (0.58–0.79) <0.001 0.80 (0.67–0.94) 0.007 0.83 (0.70–0.98) 0.031
Model 1: unadjusted model; Model 2: adjusted for age and sex; Model 3: adjusted for Model 2 + systolic blood pressure, smoking status,
alcohol intake, education levels, income levels, history of hypertension or diabetes, and physical activity; and Model 4: adjusted for Model
3 + estimated glomerular filtration rate, proteinuria, total cholesterol, and C-reactive protein. BMI, body mass index; CI, confidence inter-
val; HR, hazard ratio; MF ratio, muscle-to-fat ratio.
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ses. The sensitivity analysis results were consistent with the
main findings of the study (Supporting Information, Table S6).
Relationship of muscle-to-fat ratio with chronic
kidney disease incidence in different body mass
index groups
Further evaluations were made to assess the impact of the
MF ratio in overweight and obese subgroups classified based
on the BMI criteria. When the subjects were classified into
normal weight (BMI <23.0 kg/m2), overweight (BMI 23.0–
27.4 kg/m2), and obese (BMI ≥27.5 kg/m2) groups, a signifi-
cant gradual increase in the risk of incident CKD development
was found in those with a low MF ratio. However, in those
with a high MF ratio, the risk of CKD development in over-
weight and obese subjects was comparable with that in sub-
jects with normal BMI (Figure 1). In addition, the time to CKD
development was significantly longer in those with a high MF
ratio. This advantage against incident CKD development was
maintained in overweight and obese subjects, but not in
those with a normal BMI (Supporting Information, Figure
S4). When the incidences of CKD were stratified against the
sex-specific median values of the MF ratio and the BMI group,
the CKD incidence rate was the highest in obese subjects with
a low MF ratio and the lowest in those with normal BMI and a
high MF ratio (Figure 2).
Subgroup analysis
The relationship between the MF ratio and incident CKD was
further evaluated in subgroups stratified by age (<50 vs. ≥50
years), sex (female vs. male), hypertension (yes vs. no), eGFR
(60–79.9 vs. 80–99.9 vs. ≥100 mL/min/1.73 m2), and protein-
uria (yes vs. no). No significant interactions were found in any
of the subgroups, suggesting that the relation between the
MF ratio and incident CKD risk was consistently significant
across these subgroups (Supporting Information, Figure S5).
Follow-up loss
The overall follow-up loss rate during the whole study dura-
tion was 29.5%. However, more than 62% of the subjects
remained in the study for over 125 months (Supporting Infor-
mation, Figure S6). The proportion of subjects lost to follow-
up was comparable between the high and low MF ratio
groups [1170 (30.5%) vs. 1093 (28.4%), P = 0.051]. Changes
in address or telephone number, being too busy to attend,
and not answering telephone calls were the main reasons
of follow-up loss. Cumulative death rate between the groups
was also comparable [367 (9.6%) vs. 336 (8.7%), P = 0.114].
Discussion
In this study, the association of BMI and the MF ratio with
CKD development was investigated in a general population
cohort with preserved kidney function. Metabolic indices
were positively correlated with BMI and negatively correlated
to the MF ratio. BMI did not show a significant relationship
Figure 2 The prevalence of CKD according to sex-specific median of the
MF ratio in different BMI groups (P for trend <0.001). BMI, body mass
index; CKD, chronic kidney disease; MF ratio, muscle-to-fat ratio.
*World Health Organization obesity classification for Asian population
was used: normal (BMI <23.0 kg/m2), overweight (BMI 23.0–27.4 kg/
m2), and obese (BMI ≥27.5 kg/m2).
Figure 1 Comparison of risk for CKD development according to combina-
tion of BMI and sex-specific median values of the MF ratio (low BMI with
high MF ratio as reference group). BMI, body mass index; CI, confidence
interval; CKD, chronic kidney disease; HRs, hazard ratios; MF ratio, mus-
cle-to-fat ratio.
†
World Health Organization obesity classification for Asian
population was used: normal (BMI <23.0 kg/m2), overweight (BMI 23.0–
27.4 kg/m
2
), and obese (BMI ≥27.5 kg/m2).
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with CKD development after full adjustment, whereas the in-
crease in the MF ratio was clearly associated with a de-
creased risk of CKD development. In addition, the impact of
the MF ratio on CKD development was more definite in over-
weight or obese subjects than in those with a normal BMI.
Previous studies evaluating the effect of adiposity on CKD
development have shown conflicting results. Obesity defined
by BMI was significantly associated with an increased risk of
incident CKD in most of the studies. This association was ob-
served not only in cases when increased BMI was accompa-
nied by deranged metabolic features such as dyslipidaemia
and diabetes but also in metabolically healthy individuals
who do not have features of metabolic disease other than be-
ing overweight.27–29 However, several other studies failed to
show such a relationship. In a prospective cohort study (the
Framingham Offspring Study), increased BMI itself was not
an independent risk factor for stage 3 CKD development.6
In addition, an observational study of Japanese subjects with-
out kidney disease showed that obese individuals without
metabolic complications were not exposed to a higher risk
of incident CKD compared with non-obese healthy subjects.30
These controversies could be based on the fact that BMI is a
surrogate measure with considerable limitations in assessing
adiposity.7,8 As BMI is not a surrogate of fat mass alone but
represents the composite of fat, muscle, bone, and fluid,
assessing the effect of each component of BMI is not possi-
ble.31 This limitation of BMI should be further emphasized
on the basis of recent reports showing that excessive adipos-
ity is metabolically harmful whereas muscle mass plays a ben-
eficial role. The findings of this study demonstrating that BMI
correlates positively with the FMI but negatively with the MF
ratio support the notion that the associations of BMI with
body composition factors could be diverse.
The impact of the MF ratio on outcome has been previ-
ously evaluated in patients with high-risk factors for
sarcopenia, such as advanced CKD.14 By evaluating patients
with stage 3–5 CKD not yet treated with dialysis, Lin et al.
showed that lean tissue index rather than BMI alone provided
better risk prediction of cardiovascular outcome in these pa-
tients. Moreover, they found that a high lean/fat tissue index
was associated with the best outcomes. Another recent re-
port showed that in patients undergoing maintenance
haemodialysis, the mortality risk is increased in those with a
high BMI and increased body fat but decreased in those with
a high BMI and high muscle mass.32 Despite these previous
reports, studies evaluating the effect of body composition
on renal outcome in relatively healthy subjects with pre-
served renal function are lacking. The results of the present
study suggest that the balance of fat mass and muscle mass
could be a considerable factor when assessing the risk of kid-
ney function decline in the general population.
Several possible mechanisms by which the MF ratio affects
kidney function can be postulated. Decrease in muscle mass is
frequently linked with chronic inflammation.33 Increased low-
grade systemic inflammation or pro-inflammatory cytokines
related to low muscle mass may consequently induce endo-
thelial dysfunction, leading to a decrease in kidney func-
tion.34,35 In addition, skeletal muscle is the primary site of
insulin-mediated glucose uptake. A previous report has shown
that greater muscle mass is clearly associated with increased
insulin sensitivity.36 As insulin resistance and related meta-
bolic complications are well-known factors that damage the
kidneys, healthier metabolic features associated with in-
creased muscle mass can contribute to preventing kidney
function decline. The circulating levels of fasting glucose,
HbA1c, and HOMA-IR were significantly lower in subjects with
a high MF ratio in this study, supporting this possibility. Fur-
thermore, recent studies have suggested that the skeletal
muscle is an endocrine organ. Myokines, which are peptides
released from the skeletal muscle, have been observed to af-
fect kidney function, a phenomenon proposed as muscle–
kidney crosstalk.37 A well-recognized myokine, irisin, has been
demonstrated to improve kidney energy metabolism and pre-
vent kidney damage in mice. On the other hand, increased fat
mass is associated with chronic inflammation and induces
negative metabolic effects such as impaired glucose tolerance
and deranged lipid profile.38 These increased inflammation
and negative metabolic effects may lead to structural changes
in the kidney, such as mesangial expansion and renal fibro-
sis.39 Supporting this notion, the present study demonstrated
that the levels of CRP, LDL-C, and triglyceride were signifi-
cantly higher in subjects with a low MF ratio. In addition, in-
creased fat mass may confer adverse haemodynamic effects
on the kidney, inducing higher filtration fraction and increased
glomerular capillary pressure.40 Considering these beneficial
and adverse properties of muscle and fat mass, the net addi-
tive effect of the balance between the two body components
could have an impact on kidney function.
This study has several limitations. First, body composition
was measured using BIA only. Dual-energy X-ray absorptiom-
etry is also considered a reliable method for body composi-
tion assessment.41 Nevertheless, previous reports have
confirmed that multifrequency BIA systems can provide accu-
rate muscle mass and fat mass values that are comparable
with those measured using dual-energy X-ray absorptiometry
in various populations.42,43 In addition, the Asian Working
Group of Sarcopenia supports the use of BIA for body compo-
sition assessment in community-based settings, owing to its
simplicity and reliability.44 Second, a single measurement of
body composition at baseline was used for the analysis. As
the body composition changes over time, values obtained
during a longer follow-up period may provide a more accu-
rate body composition status. Further investigations consid-
ering body composition indices as time-dependent factors
would be needed. Third, evaluations among underweight in-
dividuals were not possible due to the small size of this group
(120, 1.6%). Further assessments would be needed to verify
whether the findings of this study are maintained among
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those with low BMI. Fourth, although the creatinine levels
had been standardized to isotope dilution mass spectrometry
reference method values through two different calibration
formulae, possibilities of bias still remain. Lastly, owing to
the observational study design, a clear causal relationship be-
tween a high MF ratio and a lower risk of incident CKD could
not be established. Nevertheless, a high MF ratio was inde-
pendently associated with an increased risk of CKD develop-
ment even after adjustments for extensive covariates,
lowering the chance of bias.
In conclusion, a high MF ratio is associated with a de-
creased risk of incident CKD in subjects with normal kidney
function. This association is more prominent in overweight-
to-obese subjects. Therefore, in addition to body mass, the
balance between body composition components would need
to be considered when stratifying the risk of CKD
development.
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